Your session is about to expire
← Back to Search
4D-125 for Retinitis Pigmentosa
Study Summary
This trial is studying a treatment for non-syndromic X-linked retinitis pigmentosa, a disease that causes blindness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have at least one eye that can be treated with an injection and my vision is between 20/32 and 20/200.I have at least one eye suitable for injection and both eyes can see well enough (about 20/200 vision).I am a male and at least 6 years old.My genetic test confirmed I have an RPGR mutation.I'm sorry, but "Key" is not a clear criterion. Could you please provide more context or information about the criterion you are referring to?I am a male and at least 12 years old.
- Group 1: 4D-125 Dose Expansion
- Group 2: Observational
- Group 3: 4D-125 Dose Exploration
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have been accepted into this clinical research endeavor?
"Affirmative. Per the clinicaltrials.gov page, this medical trial is currently enlisting participants after being posted on June 9th 2020 and recently edited on August 18th 2022. 43 individuals need to be gathered from 8 different sites for the study's completion."
Is this clinical experiment actively accepting participants?
"Clinicaltrials.gov indicates that this study is seeking enrollees and was initially made available on June 9th, 2020 with the last update occuring on August 18th 2022."
How many sites offer access to this trial?
"Participants may select from 8 research centres, such as the Casey Eye Institute and Oregon Health and Science University in Portland. Additionally, there are Retina Foundation of the Southwest located in Dallas and Duke University Eye Center/Dept. of Ophthalmology in Durham among several other options available."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Columbia University Medical Center/Edward Harkness Eye Institute: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger